This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

MIRACL study, atorvastatin

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Summary points regarding this study are presented:

  • objective - to determine whether atorvastatin, 80 mg/d, initiated 24-96 hours after an acute coronary syndrome, reduces death and nonfatal ischaemic events
  • trial design - randomized double-blind, follow-up through 16 weeks
  • patients - 3086 patients (aged 18 years or older) with unstable angina or nonQ-wave acute myocardial infarction
  • main outcome measures - primary end point defined as death, nonfatal acute myocardial infarction, recurrent myocardial ischaemia with objective evidence and requiring emergency hospitalisation, or cardiac arrest with resuscitation
  • results - no significant differences in risk of death, nonfatal myocardial infarction, or cardiac arrest between the atorvastatin group and the placebo group, although the atorvastatin group had a lower risk of symptomatic ischaemia with objective evidence and requiring hospitalisation (6.2% Vs 8.4%; RR, 0.74; 95% CI, 0.57-0.95; P=.02)
  • conclusion - lipid lowering treatment with atorvastatin, 80mg/d, for patients with acute coronary syndrome, reduces ischaemic events in the first 16 weeks, mostly recurrent symptomatic ischaemic requiring hospitalisation


  1. Schwartz GC et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes - the MIRACL Study: A randomized controlled trial. JAMA 2001; 285 (13): 1711-1718.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.